Orthocell Ltd
Orthocell Ltd (ASX:OCC) is listed on the Australian Securities Exchange.
See more information about Orthocell Ltd
Orthocell granted key US divisional patent for CelGro®
Orthocell Ltd (ASX:OCC) has received a new US divisional patent for CelGro® that covers the method of manufacture of collagen medical devices and as an aid in the surgical repair of soft tissue injuries.
The patents entitled ‘Method for Producing a Collagen Membrane and Uses Thereof' provides additional important intellectual property (IP) to protect the CelGro® platform for soft tissue regeneration and repair applications and expires in June 2033.
Orthocell has already been granted patents for CelGro® in the US, Canada, Europe, China, Japan, Singapore, Australia and New Zealand with CelGro® dental (recently renamed Striate+) approved for use in the US, Europe and Australia.
According to the company, the global addressable market for CelGro® is more than US$10 billion and is growing.
"Strengthens IP position"
Orthocell managing director Paul Anderson, said: "This is an important patent that further protects and strengthens our IP position for CelGro® providing greater layers of protection.
"This patent also complements the recent market approval of the first CelGro® product, Striate+ for dental bone and soft tissue repair procedures approved in the US, EU and Australia."
Other Orthocell Ltd news
- Orthocell shares sharply higher on back of positive results in CelGro® nerve repair clinical study
2020-11-20 - Orthocell submits Australian TGA regulatory application for CelGro® nerve regeneration platform
2020-07-30 - Orthocell's Ortho-ATI™ cell therapy features in respected ISAKOS textbook
2020-05-15 - Orthocell completes US 510(k) submission to FDA for CelGro® bone regeneration product
2020-05-12 - Orthocell secures European patent for its tissue regeneration technology
2018-05-25
